Xamoterol, a selective partial β1-AR agonist, was shown to rescue social recognition deficits in an AD mouse model (APP) by activating the protein kinase A (PKA)/phosphorylated cAMP-response element-binding protein (phospho-CREB) signaling cascade. This evidence concerns the gene APP and Alzheimer disease.